Atlas FDA

Magtrace and Sentimag Magnetic Localization System

FDA premarket approval P160053/S009 · decided 2024-04-15

Approval details

PMA number
P160053
Supplement
S009
Supplement type
Normal 180 Day Track
Supplement reason
Change Design/Components/Specifications/Material
Trade name
Magtrace and Sentimag Magnetic Localization System
Generic name
Lymph node location system during sentinel biopsy procedure
Applicant
Endomagnetics Ltd.,
Date received
2023-06-12
Decision date
2024-04-15
Days to decision
308 days
Decision code
APPR
Product code
PUV
Advisory committee
General, Plastic Surgery
Expedited review
No
Location
Cambridge
Statement
using a new dose (1 ml) of Magtrace with Sentimag® Magnetic Localization System to assist in localizing lymph nodes draining a tumor site, as part of a sentinel lymph node biopsy procedure, in patients with breast cancer undergoing a mastectomy or lumpectomy

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
Magseed Pro Magnetic Marker System (K232865)Endomagnetics Ltd.,2024-06-28
Sentimag System (K222832)Endomagnetics Ltd.,2023-01-21
Magseed Magnetic Marker Systtem (K173587)Endomagnetics Ltd.,2018-02-16
Magseed Magnetic Marker System (K163541)Endomagnetics Ltd.,2017-01-13
Sentimag System, Sentimark Magnetic Marker Systerm (K153044)Endomagnetics Ltd.,2016-03-02